Impacts of Monoallelic and Biallelic <i>DDX41</i> Mutations on Hematopoiesis and the Development of Myeloid Malignancies

DDX41 is a newly identified leukemia predisposition gene encoding an RNA helicase, whose germline mutations are tightly associated with late-onset myeloid malignancies. Importantly, germline DDX41 mutations were also found in as many as ~7 % of sporadic cases of high-risk MDS, conferring the largest germline risk for myeloid malignancies. In typical cases, a germline loss-of-function allele is compounded by a somatic missense mutation affecting the helicase domain in the remaining allele (p.R525H). However, the molecular mechanism by which DDX41 mutations lead to myeloid neoplasms have not fully been elucidated. To clarify the role of these distinct DDX41 alleles, we generated mice models carrying either or both of conditional/constitutive Ddx41 knock-out (KO) and conditional R525H knock-in alleles. Next, by crossing these mice and further breeding with Rosa26-CreERT2 transgenic mice, we engineered mice that were wild-type for Ddx41 (Ddx41+/+), heterozygous Ddx41 KO (Ddx41+/-), homozygous Ddx41 KO (Ddx41-/-), heterozygous for the Ddx41 R525H mutation (Ddx41R525H/+), or hemizygous for the Ddx41 R525H mutation (Ddx41R525H/-), in which expression of the mutant allele was induced by tamoxifen administration. In noncompetitive BM transplantation, most of the recipient mice that were transplanted with BM from Ddx41-/- or Ddx41R525H/- mice died within a month after CreERT2 induction due to severe BM failure, which was not observed in mice transplanted with BM from Ddx41+/+, Ddx41+/- or Ddx41R525H/+ mice. Transcriptome analysis revealed that stem cells (Kit+Sca-1-Linlow cells) derived from Ddx41R525H/- BM-transplanted mice exhibited a significant upregulation of ribosomal genes and several snoRNA genes compared with those derived from Ddx41+/+ BM-transplanted mice, which could result in abnormal ribosome biogenesis. In addition, Ddx41R525H/--derived Gr1+CD11b+ myeloid cells showed a significant upregulation of genes involved in cGAS-STING signaling pathways compared with Ddx41+/+-derived myeloid cells. However, the survival and cytopenia and the ribosome biogenesis in the stem cells in Ddx41R525H/- BM-transplanted mice were improved only marginal when the intact Sting alleles were deleted. These results suggest that the impact of the cGAS-Sting signaling on these phenotypes was, if ever, very small, highlighting the role of Sting-independent mechanisms. In long-term observations, mice transplanted with Ddx41+/- or Ddx41R525H/+ BM exhibited significantly lower white blood cell counts and anemia, both in primary and subsequent transplantations, although they did not exhibit significant transcriptional changes relative to the wild-type control animals until just before the onset of disease. Some of these mice developed MDS-like phenotypes, including ineffective hematopoiesis and erythroid dysplasia. Stem cells from these mice showed abnormal ribosome biogenesis and reduced expression of interferon response genes. It may be that clones that adapted to the inflammatory environment were gradually selected and contribute to their clonal advantage. Given that the MDS clones with the DDX41 R525H somatic allele are commonly observed as a small subclone in patients, we next co-transplanted Ddx41+/+- and Ddx41525H/--derived BM cells with Ddx41+/+- or Ddx41+/--derived BM cells at the ratio of 1:9. The recipient mice showed significantly reduced WBC counts when Ddx41+/+- or Ddx41+/- were co-transplanted with Ddx41525H/- -derived BM, suggesting that Ddx41525H/--derived hematopoietic cells have negative effect on normal hematopoiesis. In order to assess the crosstalk between biallelic Ddx41 mutant cells and their microenvironment cells harboring monoallelic Ddx41 mutations, we co-transplanted Ddx41+/+- or Ddx41525H/--derived BM cells with Ddx41+/--derived BM cells into the constitutive heterozygous Ddx41 KO mice. The phenotypic and molecular characteristics of these mice are under investigation. In summary, conditionally introduced compound loss-of function and R525 alleles caused severe BM failure, whereas heterozygous Ddx41 loss-of function and R525H knock-in alleles are compatible with hematopoiesis, although associated with impaired hematopoiesis and the development of MDS with aging, where an attenuated inflammatory response and ribosome functions may play important roles.

Authors

Institutions

Publication Details

Journal
Blood
Published
2024-11-05
DOI
https://doi.org/10.1182/blood-2024-209922
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Impacts of Monoallelic and Biallelic DDX41 Mutations on Hematopoiesis and the Development of Myeloid Malignancies

Ayana Kon, Akihiro Tomita, Nobuyuki Kakiuchi, Hideki Makishima et al.
Blood
Acute Myeloid Leukemia Research
article

Impacts of Monoallelic and Biallelic DDX41 Mutations on Hematopoiesis and the Development of Myeloid Malignancies

Ayana Kon, Akihiro Tomita, Nobuyuki Kakiuchi, Hideki Makishima, Masahiro Nakagawa, Seishi Ogawa, Yasuhito Nannya, Haruhiko Koseki, Keisuke Kataoka, Manabu Nakayama
article en

Abstract

DDX41 is a newly identified leukemia predisposition gene encoding an RNA helicase, whose germline mutations are tightly associated with late-onset myeloid malignancies. Importantly, germline DDX41 mutations were also found in as many as ~7 % of sporadic cases of high-risk MDS, conferring the largest germline risk for myeloid malignancies. In typical cases, a germline loss-of-function allele is compounded by a somatic missense mutation affecting the helicase domain in the remaining allele (p.R525H). However, the molecular mechanism by which DDX41 mutations lead to myeloid neoplasms have not fully been elucidated. To clarify the role of these distinct DDX41 alleles, we generated mice models carrying either or both of conditional/constitutive Ddx41 knock-out (KO) and conditional R525H knock-in alleles. Next, by crossing these mice and further breeding with Rosa26-CreERT2 transgenic mice, we engineered mice that were wild-type for Ddx41 (Ddx41+/+), heterozygous Ddx41 KO (Ddx41+/-), homozygous Ddx41 KO (Ddx41-/-), heterozygous for the Ddx41 R525H mutation (Ddx41R525H/+), or hemizygous for the Ddx41 R525H mutation (Ddx41R525H/-), in which expression of the mutant allele was induced by tamoxifen administration. In noncompetitive BM transplantation, most of the recipient mice that were transplanted with BM from Ddx41-/- or Ddx41R525H/- mice died within a month after CreERT2 induction due to severe BM failure, which was not observed in mice transplanted with BM from Ddx41+/+, Ddx41+/- or Ddx41R525H/+ mice. Transcriptome analysis revealed that stem cells (Kit+Sca-1-Linlow cells) derived from Ddx41R525H/- BM-transplanted mice exhibited a significant upregulation of ribosomal genes and several snoRNA genes compared with those derived from Ddx41+/+ BM-transplanted mice, which could result in abnormal ribosome biogenesis. In addition, Ddx41R525H/--derived Gr1+CD11b+ myeloid cells showed a significant upregulation of genes involved in cGAS-STING signaling pathways compared with Ddx41+/+-derived myeloid cells. However, the survival and cytopenia and the ribosome biogenesis in the stem cells in Ddx41R525H/- BM-transplanted mice were improved only marginal when the intact Sting alleles were deleted. These results suggest that the impact of the cGAS-Sting signaling on these phenotypes was, if ever, very small, highlighting the role of Sting-independent mechanisms. In long-term observations, mice transplanted with Ddx41+/- or Ddx41R525H/+ BM exhibited significantly lower white blood cell counts and anemia, both in primary and subsequent transplantations, although they did not exhibit significant transcriptional changes relative to the wild-type control animals until just before the onset of disease. Some of these mice developed MDS-like phenotypes, including ineffective hematopoiesis and erythroid dysplasia. Stem cells from these mice showed abnormal ribosome biogenesis and reduced expression of interferon response genes. It may be that clones that adapted to the inflammatory environment were gradually selected and contribute to their clonal advantage. Given that the MDS clones with the DDX41 R525H somatic allele are commonly observed as a small subclone in patients, we next co-transplanted Ddx41+/+- and Ddx41525H/--derived BM cells with Ddx41+/+- or Ddx41+/--derived BM cells at the ratio of 1:9. The recipient mice showed significantly reduced WBC counts when Ddx41+/+- or Ddx41+/- were co-transplanted with Ddx41525H/- -derived BM, suggesting that Ddx41525H/--derived hematopoietic cells have negative effect on normal hematopoiesis. In order to assess the crosstalk between biallelic Ddx41 mutant cells and their microenvironment cells harboring monoallelic Ddx41 mutations, we co-transplanted Ddx41+/+- or Ddx41525H/--derived BM cells with Ddx41+/--derived BM cells into the constitutive heterozygous Ddx41 KO mice. The phenotypic and molecular characteristics of these mice are under investigation. In summary, conditionally introduced compound loss-of function and R525 alleles caused severe BM failure, whereas heterozygous Ddx41 loss-of function and R525H knock-in alleles are compatible with hematopoiesis, although associated with impaired hematopoiesis and the development of MDS with aging, where an attenuated inflammatory response and ribosome functions may play important roles.

BloodVol. 144(Supplement 1)
Shinshu University (JP), Keio University (JP), Kyoto University (JP), Shiga University of Medical Science Hospital (JP), Kazusa DNA Research Institute (JP), RIKEN Center for Integrative Medical Sciences (JP), The University of Tokyo (JP)
Bristol-Myers Squibb, AstraZeneca, Alexion Pharmaceuticals, Celgene, Japan Blood Products Organization, Nippon Shinyaku, JCR Pharmaceuticals, Eisai, Meiji Seika Pharma, Mitsubishi Foundation, Shionogi, Otsuka Pharmaceutical, Nakatani Foundation for Advancement of Measuring Technologies in Biomedical Engineering, Teijin Pharma, Ono Pharmaceutical, SymBio Pharmaceuticals Limited, Chugai Pharmaceutical, Daiichi Sankyo Europe
Good health and well-being
Openalex Percentile: Top 64%
Acute Myeloid Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.